Gara Jalqabaatti › Saree Oljoo › Minnesota › Minneapolis
Qorannoo klinikaalii Saree Oljoo Minneapolis, MN keessatti
Qorannoo 27 Saree Oljoo f Minneapolis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Minneapolis VA Medical Center, Minneapolis
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Minnesota Oncology Hematology, P.A., Minneapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Minnesota Oncology Hematology P A, Minneapolis
- Allina Hlth Cancer Inst Minneapolis, Minneapolis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · Miili 5 fagaatti
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Minnesota, Masonic Cancer Center, Minneapolis
PRE-ISPY Phase I/II Oncology Platform Program
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- HealthPartners Frauenshuh Cancer Center, Saint Louis Park · Miili 5 fagaatti
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Minneapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Metro-Minnesota Community Clinical Oncology, Saint Louis Park · Miili 5 fagaatti
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Healthpartners Regions Specialty Clinics, Saint Louis Park · Miili 5 fagaatti
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Metro-MN Comm. Onc. Res Consortium, Saint Louis Park · Miili 5 fagaatti
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of Minnesota Medical Center, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Minnesota Masonic Cancer Center, Minneapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Local Institution - 0372, Minneapolis
Fast-Her: Fasting Effects on Breast Cancer Treatment
Namoota walitti qabaa jira
- University of Minnesota, Minneapolis
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Allina Health System DBA Virginia Piper Cancer Institute, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · Miili 5 fagaatti
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Minnesota Oncology Hematology, P.A., Minneapolis
Axelopran for Advanced Cancer in Patients Receiving Opioids
Namoota walitti qabaa jiraSadarkaa 2
- HealthPartners Frauenshuh Cancer Research Center, Saint Louis Park · Miili 5 fagaatti
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Namoota walitti qabaa jiraQorannoo ilaalaa
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Allina Health Cancer Institute, Minneapolis
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Metro Minnesota Community Oncology Consortium (MMCORC), Saint Louis Park · Miili 5 fagaatti
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Namoota walitti qabaa jiraSadarkaa 3
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Namoota walitti qabaa jiraQorannoo ilaalaa
- Minnesota Oncology, Minneapolis
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Minneapolis keessatti
- Kansara Qara'a Non-Small CellQorannoo 27
- Kansarii OvariiQorannoo 24
- Kansarii ProstateQorannoo 23
- Saree (Gosoota Hunda)Qorannoo 22
- Cufama OnneeQorannoo 21
- Leukemia Myeloidii HamaaQorannoo 20
- Dhibee QaraQorannoo 20
- Kansarii ColorectalQorannoo 19
- Kansa EndometiriyaaliiQorannoo 18
- Dhibee ParkinsonQorannoo 17
- Dhibee Onneessaa fi DhiigaQorannoo 15
- Dhukkuba Arterii KoronariyaaQorannoo 13
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.